ADC Therapeutics (NYSE: ADCT) Exceeds Q3 2026 Earnings Expectations with ZYNLONTA Growth

• Adjusted loss per share of $0.16 was smaller than the $0.21 analyst estimate.
• Revenue reached $21.72 million, surpassing the $18.7 million estimate.
• ADC Therapeutics holds $189.2 million in cash, extending its operational funding into 2029.

ADC Therapeutics (NYSE: ADCT) is a drug company developing treatments for blood cancers. Its main product, ZYNLONTA, treats certain B-cell cancers. In the third quarter of 2026, the company reports an adjusted loss of $0.16 per share, smaller than the $0.21 loss analysts expected, as highlighted by Zacks.

The quarterly loss also narrows from $0.30 per share a year earlier. Revenue reaches $21.72 million, up from $16.43 million and above the $18.7 million estimate. ADC Therapeutics beats both earnings-per-share and revenue estimates in three of the past four quarters.

Net product revenue totals $21 million for the quarter. ADC Therapeutics holds $189.2 million in cash and cash equivalents as of September 30. The company says a financial restructuring strengthens its balance sheet and gives it enough expected cash to fund operations into 2029.

ADC Therapeutics continues to study ZYNLONTA for other B-cell cancers, with research scheduled for presentation at ASH 2026. In Japan, partner Tanabe’s application for marketing authorization could support future regulatory and sales milestones. The stock’s price-to-sales ratio is 2.24, meaning its market value is 2.24 times its annual sales.